Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


I'M SO DISCOURAGED
Mar 12, 2002

I recently read that in the next year there still will not be any new drugs for those of us will resistant virus. What has happened to t-20, BMS-protease inhibitor. Is there anywhere I can find an accurate timeline for drugs to help those of us with resistant virus?

Response from Dr. Boyle

Both T-20 and atazanavir (the BMS protease inhibitor) are progressing in clinical trials and, if things go well, it is expected that they will be approved within a year or so. Tipranavir (a protease inhibitor being developed by BI and also with a favorable resistance profile), DPC 083 (a non-nucleoside being developed by BMS) and several other drugs are also moving through clinical trials. Between now and the end of the year, there should be more information about these and other drugs, and hopefully it will be favorable.



Previous
Once a day regimen
Next
stopping the meds

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement